Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma

HÁJEK, Roman, Evžen GREGORA, Vladimír MAISNAR, Jiří MINAŘÍK, P. PAVLÍČEK, Luděk POUR, J. RADOCHA, M. SCHÜTZOVÁ, J. STRAUB, Vlastimil ŠČUDLA, Zdeněk ADAM and Petra MÁJKOVÁ. Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma. In 16th Congress of the European Hematology Association. 2011. ISSN 0390-6078.

Basic information

Original name

Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma

Authors

HÁJEK, Roman, Evžen GREGORA, Vladimír MAISNAR, Jiří MINAŘÍK, P. PAVLÍČEK, Luděk POUR, J. RADOCHA, M. SCHÜTZOVÁ, J. STRAUB, Vlastimil ŠČUDLA, Zdeněk ADAM and Petra MÁJKOVÁ

Edition

16th Congress of the European Hematology Association, 2011

---

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 6.424

Organization unit

University Hospital Brno

ISSN

Keywords in English

multiple myeloma; lenalidomide

---

Abstract

V originále

Lenalidomide is active and generally well-tolerated in relapsed/refractory myeloma. These results support the approved 25 mg once-daily dosing of lenalidomide on days 1- 21 of a 28 day cycle in patients with relapsed/refractory multiple myeloma and indicate that every-other-day dosing compromises response with no significant difference in tolerability.